Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

Ann Calby Miller net worth and biography

Ann Miller Biography and Net Worth

Director of Puma Biotechnology

Dr. Miller was appointed as a director of Puma Biotechnology on November 12, 2019. Since March 2019, she has served as a member of the Board of Directors of Inovio Pharmaceuticals, Inc., a publicly held biotechnology company focused on the discovery, development, and commercialization of its synthetic DNA technology targeted against cancers and infectious diseases. Since October 2020, she has served as a member of the Board of Directors of Allena Pharmaceuticals, a publicly held biotechnology company focused on developing a pipeline of first-in-class, oral, non-absorbed enzyme therapeutic candidates to treat patients with rare and severe metabolic disorders that affect the kidney.

Prior to that, Dr. Miller worked at Sanofi S.A. from 2012 until her retirement in September 2018, serving as Vice President of Marketing and Vice President of Global Marketing, Oncology Division. From 2009 to 2011, Dr. Miller was at Eisai Co., Ltd and served as Senior Vice President of Pharmaceutical Services and Senior Vice President of the Primary Care and Specialty Business unit. Dr. Miller previously served in management roles in Global and U.S. Marketing at Amgen Inc. over a period of six years and in positions of increasing responsibility at Merck & Co., Inc. over a period of 16 years.

Dr. Miller received an M.D. from the Duke University School of Medicine and a B.A. in chemistry with honors from Duke University. She was selected as a director because of her broad commercial background in the biopharmaceutical industry and her clinical training and experience.

What is Ann Calby Miller's net worth?: The estimated net worth of Ann Calby Miller is at least $35,403.50 as of June 10th, 2021. Ms. Miller owns 12,874 shares of Puma Biotechnology stock worth more than $35,404 as of December 21st. This net worth estimate does not reflect any other investments that Ms. Miller may own. Learn More about Ann Calby Miller's net worth.
How do I contact Ann Calby Miller?: The corporate mailing address for Ms. Miller and other Puma Biotechnology executives is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. Puma Biotechnology can also be reached via phone at (424) 248-6500 and via email at [email protected]. Learn More on Ann Calby Miller's contact information.
Has Ann Calby Miller been buying or selling shares of Puma Biotechnology?: Ann Calby Miller has not been actively trading shares of Puma Biotechnology within the last three months. Most recently, Ann Calby Miller sold 12,874 shares of the business's stock in a transaction on Thursday, June 10th. The shares were sold at an average price of $11.43, for a transaction totalling $147,149.82. Following the completion of the sale, the director now directly owns 12,874 shares of the company's stock, valued at $147,149.82. Learn More on Ann Calby Miller's trading history.
Who are Puma Biotechnology's active insiders?: Puma Biotechnology's insider roster includes Alan Auerbach (CEO), Douglas Hunt (Insider), Ann Miller (Director), Maximo Nougues (CFO), and Alvin Wong (Insider). Learn More on Puma Biotechnology's active insiders.
Are insiders buying or selling shares of Puma Biotechnology?: During the last year, insiders at the biopharmaceutical company sold shares 11 times. They sold a total of 174,074 shares worth more than $667,379.98. The most recent insider tranaction occured on August, 12th when Director Michael Patrick Miller sold 23,358 shares worth more than $81,519.42. Insiders at Puma Biotechnology own 23.7% of the company. Learn More about insider trades at Puma Biotechnology.
Information on this page was last updated on 8/12/2024.

Ann Calby Miller Insider Trading History at Puma Biotechnology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/10/2021	Sell	12,874	$11.43	$147,149.82	12,874

Ann Calby Miller Buying and Selling Activity at Puma Biotechnology

Puma Biotechnology Company Overview

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Today's Range

Now: $2.75

$2.74

$2.89

50 Day Range

MA: $2.95

$2.42

$3.39

2 Week Range

Now: $2.75

$2.22

$7.73

Volume

360,487 shs

Average Volume

463,782 shs

Market Capitalization

$134.99 million

P/E Ratio

5.73

Dividend Yield

N/A

Beta

1.08

First JFK… next Elon?

From Porter & Company | Ad